Significant advantage of targeted antitumoral treatment consists in the possibility to restrict maximum therapeutic efficacy to the malignant cell population by reducing toxicity in healthy tissues. Using different clinical models for aggressive medullary thyroid carcinoma (MTC), we have recently identified peptide ligands that bind highly selective to tumor cells. By linking the most convincing SRESPHP peptide to an adenoviral (Ad) vector expressing the MTC-related oncogene inhibitor RETDTK, gene transfer was specifically directed to neoplastic tissue after systemic virus administration. We show that peptide-mediated delivery of RETDTK significantly enhanced apoptosis, resulting in a strong inhibition of orthotopic and xenograft tumor growth. Conversely, tumors treated with controls expanded their initial size without notable cell death. According to the therapeutic effect, strong virus accumulation was found exclusively in thyroid carcinomas. Strikingly, application of native tropism depleted viral vector linked to tumor-selective peptide was accompanied by a substantial reduction of Ad binding to the liver. Of note, single systemic injection of a low dose (10e8 pfu/mouse) of MTC-specific Ad.RETDTK induced regression of multiple tumors at different sites in all treated animals. In sum, our results open up the possibility for an efficient cancer cell-specific therapy of primary MTC, their migrating populations and potentially metastases.
INTRODUCTION
Tumor formation and progression occurs through a range of defects that develop both within and outside the cancer cell. Although defects in cell signaling pathways allow malignant cells to alter their normal programmes of proliferation, transcription, growth, migration, differentiation and death, changes in the surrounding stroma and immune response enable the tumor to expand, form new blood vessels and spread to other organs. Among well-differentiated thyroid tumors, medullary thyroid carcinoma (MTC) that originates from calcitonin secreting parafollicular C cells, either sporadically or as a component of the familial cancer syndrome multiple endocrine neoplasia type 2, is characterized by aggressive growth and early tumor spreading. 1 Currently, treatment of MTC is restricted to surgical removal of neoplastic tissue, and cure is only achieved when the disease is restricted to the thyroid gland. In contrast, patients with unresectable or metastatic cancer display a poor prognosis, and chemotherapy or radiotherapy are only palliative in this setting. 2, 3 The limited options for patients with cancer at an advanced stage show that research in developing more efficient and specific cancer killing strategies with systemic properties is a major challenge of current therapy modalities.
MTC is caused by dominant activating mutations in the RET protooncogene that encodes a transmembrane receptor of the tyrosine kinase family. 4 Concise examination led to the detection of a striking genotype-phenotype correlation between the mutated RET codon and clinical manifestation of the disease, indicating that tumorigenesis and progression is conditioned by the type of mutation. 5, 6 The most frequent mutation associated with the majority of MTC cases affects codon 634 in the cysteine-rich region of the extracellular domain of the receptor. 5 This causes ligand-independent homodimerization and constitutive autophosphorylation, and activation of the RET kinase, leading to the stimulation of a complex network of signal transduction pathways that contribute to dysregulated growth and survival. 7, 8 Activated oncogenes such as RET are highly attractive targets for the development of anticancer agents. 9 Principles of RET inhibition in MTC cells include molecular strategies to interfere with its kinase activity by small molecules [10] [11] [12] and receptor dimerization using aptamers or soluble RET ectodomain. 13, 14 As an alternative, strategies that block RET expression or autophosphorylation are highly promising. We have previously demonstrated that dominant-negative RET proteins that contain mutations in the extreme N-terminal region of the extracellular domain such as HSCR32 or Flag expressed by adenoviral (Ad) vectors inhibit receptor maturation, 15, 16 thereby preventing its transport to the membrane. These molecules proved to be highly active against MTC in cultures of human TT cells that harbor the RETC634R mutation and after inoculation of ex vivo infected tumor cells into nude mice. When administered to TT cell-derived xenograft tumors by Ad gene transfer, however, they had limited antitumoral efficacy. 16 Poor transduction efficiency of cancer cells is regarded as one of the general limitations of successful gene therapeutic approaches in clinical applications. Most tumor cells including MTC manifest a relative deficiency of Ad receptor, 17 which renders them refractory to viral infection and limits the therapeutic advantages of the vector system. With regard to this difficulty, a number of MTC-selective peptides have recently been identified 17, 18 that can be used with Ad vectors to target the site of disease more efficiently and may allow systemic cancer gene therapy.
Here, we tested the potential of the SRESPHP peptide covalently attached to the viral capsid of coxsackie-adenovirus receptor-ablated Ad vectors 19 to redirect gene transfer to rapidly growing cancer cells in vivo, and its effect on the antitumoral activity of an Ad vector carrying the transdominant human RET oncogene inhibitor RETDTK after a single systemic vector injection in mice with orthotopic murine and transplanted human MTC. This RET protein lacks the intracellular tyrosine kinase domain and was shown capable of blocking RET transautophosphorylation by forming an inactive dimer with oncogenic RET (the domain structure of the oncogene inhibitor is indicated). 20 The SRESPHP peptide ligand used was initially identified as the best binding candidate in a clinically relevant RETC634R transgenic mouse model by in vivo phage display, but also mediates efficient phage binding to human MTC cells. 18 Our results provide evidence that a combined targeting approach by peptide-mediated Ad vector delivery together with the disruption of tumor-associated oncogene activation is highly suitable for the achievement of an efficient and selective systemic antitumor response.
RESULTS AND DISCUSSION
We have earlier shown that direct injection of an Ad vector with wildtype tropism that expresses the truncated RET oncogene inhibitor DTK into orthotopic tumors of RETC634R transgenic 21, 22 induces almost 50% tumor reduction 2 weeks after treatment. 20 To investigate the effects of cancer selective Ad gene transfer vehicles under in vivo conditions, we measured the thyroid glands of tumor bearing transgenic mice after surgery with a calliper, sutured the transition and injected a tropism-modified Ad.RETDTK chemically linked through bifunctional polyethylene glycol to the synthetic SRESPHP peptide at a dose of 10e8 infectious viral particles either in the tail vein of mice or directly into the tumor lobes. The same procedure was conducted for the peptide-tagged control vector Ad.GFPL expressing the green fluorescent protein (GFP). At 14 days after treatment, mice were killed and the success of systemic MTC treatment versus intratumoral vector administration was determined by comparing the tumor size to day 0 (set as 100%). We found an obvious difference in tumor volume between mice treated systemically with therapeutic Ad.RETDTK-SRESPHP (Figure 1a , 47.8 ± 14.4% of initial volume) and Ad.GFPL-SRESPHP (131.9±24.1% of initial volume, Pp0.001). In contrast, Ad.RETDTK without peptide or with unspecific peptide did not lead to tumor reduction (100.3+14.3% and 99.7+11.6 of initial tumor volume, respectively). Importantly, growth of bilateral primary MTC was inhibited by intravenously injected Ad.RETDTK vector coupled to the specific peptide at the same efficiency as by intratumoral virus administration (Figure 1b RETDTK-SRESPHP such as spleen, kidney, lung and heart (data not shown). Selective tumor uptake of Ad vector after intravenous injection was also confirmed through the detection of bioluminescence signal of coxsackie-adenovirus receptor-depleted Ad.GFPL (expressing luciferase) linked to SRESPHP peptide using in vivo imaging (Figure 2b) . In addition to a clear labeling of cancer cells in the thyroid lobes of mice that were systemically treated with peptidetagged Ad, we observed a profound decrease of targeted vector in the liver (Figure 2b, left) , whereas Ad.GFP with native tropism (without targeting peptide), also expressing luciferase, was exclusively detectable in liver tissue (Figure 2b, right) . These data strongly suggest that peptide-mediated Ad infection leads to a substantial shift of Figure 1 Antitumor activity of tropism-modified adenoviral vector expressing RET oncogene inhibitor DTK against primary MTC after single systemic virus administration. Transgenic mice carrying a mutation of the RET protooncogene in codon 634 develop rapidly growing bilateral orthotopic MTCs. A total of 22 tumor volumes were assessed after surgical exposure of the thyroid glands in two perpendicular diameters with callipers on the day of virus injection (black column) and 14 days after treatment (white). Ad vectors linked to MTC-selective peptide were injected into the tail vein (a) or directly in the tumor lobe (b) at a dose of 10e8 PFU per mouse. The difference in the relative increase of the size of genetically coxsackie-adenovirus receptor-ablated Ad.GFPL-SRESPHP versus Ad.RETDTK-SRESPHP treated animals at day 14 was statistically significant for both injection routes (Po0.001). Tumor volume before treatment (day 0) was significantly larger than after injection of the therapeutic RETDTK vector with specific peptide (day 14); P¼0.001. Ad.RETDTK without peptide or with unspecific peptide are shown as controls. Bars represent the mean±s.d. of 15 mice in each experimental group. P-values were calculated by Student's t-test (two-sided).
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A Schmidt et al gene transfer from liver to tumor tissue, thereby enhancing antitumoral activity. In support of the tumor-restricted distribution of the SRESPHP virus, much higher GFP and Ad hexon mRNA and protein levels were found in MTC samples of animals, which received a single tail-vein injection of the specific vector, than in their livers (Figure 2c,  left) . Although, as demonstrated in Figure 2c (right), the opposite effect was apparent in tumor (no expression) and liver (strong expression) tissues when mice were systemically injected with the unspecific Ad.GFP wild-type control (right). The similar expression pattern was seen with Ad.GFP chemically linked to a mock peptide (data not shown).
Previous investigations revealed that the SRESPHP peptide used in this study, which was initially identified as the best binding candidate in murine MTC of RET transgenic mice, also selectively targets MTC cells of human origin in vitro, 18 Color bar settings from minimal to maximal bioluminescence signal for each mouse are given as indicated for a specific time point. For colocalization of the luminescent photon emission on the animal body, gray scale and pseudocolor images were merged using Berthold software. (c, upper panel) GFP expression was analyzed by semiquantitative RT-PCR on total RNA from MTC and liver tissue of transgenic mice that were either injected with the specific (left) or wild-type (right) GFP expressing adenovirus. GAPDH was used as a control. The level of AdHexon protein was determined using western blot by probing of whole-cell protein extracts with antibody against AdHexon (1:1000; Abcam, Cambridge, UK; bottom panel). Actin was used for equal loading. Ad.RETDTK-SRESPHP was seen in multiple human TT cell-derived tumors that are located at different sites (Figure 3c , bottom). These data implicate peptide-tagged Ad vectors as a powerful tool to improve the therapeutic efficacy against spreaded or secondary tumor sites.
In support of our in vivo data, the antitumoral effect of tumorselective Ad.RETDTK-SRESPHP was characterized by massive destruction of tumor tissue (Figure 4ai ; at higher magnification in ii) compared with tumors of Ad.GFPL-SRESPHP-treated mice (Figure 4b ). As oncogenic RET stimulates proliferation and blocks apoptosis, 8 and disruption of oncogenic RET activity by intratumoral transduction of primary MTC in transgenic mice with wild-type Ad.RETDTK decreased cell viability, 20 we studied whether systemic treatment with truncated RET from the targeted vector impairs pathologically altered tumors to the point that apoptosis sets in. For this purpose, we performed TdT-mediated dUTP-biotin nick end labeling assays on paraffin-embedded residual tumor tissues from tail-vein injected mice. Tumors overexpressing the RET inhibitor DTK underwent a strong apoptotic response 14 days after systemic treatment with approximately 50% green cells (Figure 4ci-iii) . A considerable number of TdT-mediated dUTP-biotin nick end labeling-positive carcinoma cells was still detectable up to 1 month 
A Schmidt et al after gene transfer (data not shown). Instead, no or single green cells were found in tumors from the control group that were injected with MTC-specific Ad.GFPL (1.9%; Po0.001), which showed continous tumor growth (Figure 4civ-vi ). These data demonstrate that the observed reduction in tumor volume induced by MTC-selective Ad.RETDTK after systemic targeting might be a consequence of an efficient inhibition of the antiapoptotic activity of oncogenic RET in vivo. Apart from therapeutic cytotoxicity seen in the tumor, we did not observe any treatment-related negative side effects in nontarget tissues, considering peptide-based Ad gene therapy as efficient and safe. This pilot study has proven that targeted Ad vector linked to short 7-mer peptides, which bind with high selectivity to cancer cells are suitable for systemic in vivo therapy against focal and widespread MTC of murine and human origin. We found an accumulation of gene delivery vector through SRESPHP in the tumors along with a reduction in the percentage of transduced liver cells, where normally the majority of circulating native adenovirus is sequestered because of a marked hepatotropism, and therefore does not reach its target. This may lead to toxic or lethal doses in patients. 23 The application of tumor-selective Ad vector through systemic routes gave comparable results to intratumoral injection regarding intracellular uptake efficiency, tumor/normal tissue ratio and therapeutic efficacy. In fact, redirection of therapeutic virus was associated with a pronounced antitumoral activity leading to regression of primary tumors at the same level as by means of direct tumor treatment. The benefit of our cancer targeting approach becomes even more apparent by the relative inefficacy of the nontagged therapeutic vector after systemic intervention coming along with sustained tumor growth.
A selective inhibitory effect of Ad.RETDTK directed against MTC was evidenced by the specific induction of apoptosis in malignant cells. We observed progressive cell death in transplanted human tumor tissues of systemically injected mice over time after therapy, which is consistent with the results from our previous experiments, 20 because of DTK-mediated inhibition of antiapoptotic RET oncogene signaling. However, despite an obvious cytotoxic effect, tumors could not be completely abolished by the selective virus, suggesting a need for more improvement. Normally, aggressive tumors like MTC use the processes of cellular recycling systems to resist conventional apoptosis-based treatment modalities, such as chemotherapy or radiation. 24 Thus, MTC treatment using peptide-linked proapoptotic Ad.RETDTK in In situ DNA fragmentation on tumor sections was detected using DeadEndTM Fluorometric TdT-mediated dUTP-biotin nick end labeling assay. The apoptotic response was assessed by counting an average number of 400 cells in pieces of 100 cells in four different fields of each focus. Three slides were counted in every case. Green-stained cells were considered to be positive using laser scanning microscopy (C0-, DNAse-treated tumor (positive control)); ci-iii, Ad.RETDTK-SRESPHP; civ-vi, Ad.GFPL-SRESPHP. ci, civ, magnification Â2; cii, cv, Â40; cii, cvi, Â63. Statistical significance was determined by one-way analysis of variance for two groups. P-values of 0.001 were deemed statistically significant. Scale bar ai, bi, C0¼500 mm; ci, civ¼200 mm; aii, bii, cii, cv¼100 mm; ciii, cvi¼20 mm.
combination with adjuvant chemotherapy could further potentiate tumor regression after systemic targeting. Moreover, such pathwayspecific therapy through inhibition of oncogenic RET is not limited to MTC treatment but may also target other human cancers where the RET tyrosine kinase is constitutively activated. 25, 26 MTC frequently metastasizes to regional lymph nodes in half of the patients and to lung, liver, bone, brain and other tissues. 27 Nevertheless, both tumor models did not show spread of metastases. But with the development of a MTC-selective Ad gene delivery system that efficiently targets multifocal tumors at different locations far away from the in vivo injection site, one crucial precondition for successful eradication of malignant cells was achieved. This is substantiated by the data from other cancer models, indicating that secondary tumors when migrating into other parts of the body are made of the same type of cells as the primary cancer. 28, 29 This suggests that our targeting strategy effective against disseminated primary tumors should be also successful against metastatic tumors.
